The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.
Robin Kate Kelley
Research Funding - Regeneron
Lillian L. Siu
Research Funding - Regeneron
Katherine Van Loon
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Regeneron (U); Sanofi
Albiruni R. A. Razak
No relevant relationships to disclose
Sharvina Ziyeh
No relevant relationships to disclose
Muralidhar Beeram
Research Funding - Regeneron
Philippe L. Bedard
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Rebecca Arcos
No relevant relationships to disclose
Bo Gao
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Lieve Adriaens
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Kyriakos P. Papadopoulos
Research Funding - Regeneron